Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer-Reference-Cited by-同舟云学术

Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer

Published:2010-12-15 Issue:24 Volume:16 Page:6169-6176
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Yao Song,Barlow William E.,Albain Kathy S.,Choi Ji-Yeob,Zhao Hua,Livingston Robert B.,Davis Warren,Rae James M.,Yeh I-Tien,Hutchins Laura F.,Ravdin Peter M.,Martino Silvana,Lyss Alan P.,Osborne C. Kent,Abeloff Martin,Hortobagyi Gabriel N.,Hayes Daniel F.,Ambrosone Christine B.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cyclophosphamide Pharmacogenomic Variation in Cancer Treatment and Its Effect on Bioactivation and Pharmacokinetics;Advances in Pharmacological and Pharmaceutical Sciences;2024-01

2. GSTP1 c.313A > G mutation is an independent risk factor for neutropenia hematotoxicity induced by anthracycline-/paclitaxel-based chemotherapy in breast cancer patients;World Journal of Surgical Oncology;2022-06-22

3. Lack of association of CYP2B6 pharmacogenetics with cyclophosphamide toxicity in patients with cancer;Supportive Care in Cancer;2022-05-24

4. Evaluating the role of GSTP1 genetic polymorphism (rs1695, 313A>G) as a predictor in cyclophosphamide-induced toxicities;Medicine;2021-03-19

5. Genetic Influences in Breast Cancer Drug Resistance;Breast Cancer: Targets and Therapy;2021-02